Enterprise Value (EV)
Paying user area
Try for free
Abbott Laboratories pages available for free this week:
- Balance Sheet: Assets
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Enterprise Value to FCFF (EV/FCFF)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Net Profit Margin since 2005
- Current Ratio since 2005
- Total Asset Turnover since 2005
- Price to Book Value (P/BV) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Abbott Laboratories for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Current Enterprise Value (EV)
Abbott Laboratories, current enterprise value calculation
| Current share price (P) | |
| No. shares of common stock outstanding | |
| US$ in millions | |
| Common equity (market value)1 | |
| Add: Preferred shares, one dollar par value, none issued (per books) | |
| Add: Noncontrolling interests in subsidiaries (per books) | |
| Total equity | |
| Add: Current portion of long-term debt (per books) | |
| Add: Long-term debt, excluding current portion (per books) | |
| Total equity and debt | |
| Less: Cash and cash equivalents | |
| Less: Investments, primarily bank time deposits and U.S. treasury bills | |
| Enterprise value (EV) | |
Based on: 10-K (reporting date: 2025-12-31).
1 Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
Historical Enterprise Value (EV)
Abbott Laboratories, EV calculation
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 Data adjusted for splits and stock dividends.
2 Closing price as at the filing date of Abbott Laboratories Annual Report.
3 2025 Calculation
Common equity (market value) = Share price × No. shares of common stock outstanding
= ×
The information presents a five-year trend of several financial metrics, including common equity market value, total equity, total equity and debt, and enterprise value. Overall, enterprise value exhibits fluctuations mirroring changes in the underlying equity and debt components, with a general pattern of initial decline followed by growth and a subsequent decrease.
- Enterprise Value Trend
- Enterprise value decreased from US$213,980 million in 2021 to US$192,330 million in 2022, representing a decline of approximately 10.1%. It then increased to US$205,452 million in 2023, continued to grow to US$240,390 million in 2024, and subsequently decreased to US$199,616 million in 2025. This suggests potential volatility influenced by market conditions and company performance.
- Equity Components
- Common equity (market value) followed a similar pattern to enterprise value, decreasing from US$205,957 million in 2021 to US$185,508 million in 2022, increasing to US$197,828 million in 2023, peaking at US$233,995 million in 2024, and then declining to US$194,985 million in 2025. Total equity mirrored this trend, remaining closely aligned with the market value of common equity throughout the period.
- Debt Influence
- Total equity and debt increased from US$224,229 million in 2021 to US$248,357 million in 2024, before decreasing to US$208,555 million in 2025. The increase in total equity and debt between 2021 and 2024 contributed to the growth in enterprise value during that period. The subsequent decrease in total equity and debt in 2025 aligns with the decline in enterprise value observed in the same year.
- Relationship between Metrics
- Enterprise value consistently remains close to the sum of total equity and debt, indicating that debt plays a significant role in the company’s overall valuation. The fluctuations in enterprise value are largely explained by the combined changes in equity and debt levels.
The observed trends suggest a dynamic valuation influenced by both equity market performance and debt management. The decrease in enterprise value in the final year warrants further investigation to determine the underlying causes and potential implications.